Growing prevalence of target diseases is expected to drive the growth of global microbiome therapeutics market in the forecast period, 2023-2027.
According to TechSci Research report, “Microbiome Therapeutics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027”, the global microbiome therapeutics market is anticipated to grow at an impressive rate in the forecast period, 2023-2027. This can be ascribed to the potential of microbiome therapeutics in addressing the unmet needs of existing treatment options. Additionally, microbiome therapeutics products are a safer alternative as compared to the conventional drug treatments. Similarly, increasing research & development activities and funding related to microbiome therapeutics is expected to create lucrative opportunities for the growth of global microbiome therapeutics market during the forecast period.
However, the stringent regulatory landscape related to therapeutic drug application filing, approvals, clinical trials, among others can slow down the market growth. Additionally, safety concerns associated with the use of live biotherapeutic products can further restrict the market growth. Similarly there are challenges related to manufacturing and storage of microbial products which pose a major threat to the overall market growth.
Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on “MICROBIOME THERAPEUTICS MARKET“
The global microbiome therapeutics market can be segmented into by type, by application and region.
Based on type, the market for microbiome therapeutics can be bifurcated into FMT and microbiome drugs. In 2021, the market was dominated by faecal microbiota therapy (FMT). The widespread use of FMT in the management of C. difficile infection is associated with its supremacy.
Based on application, the market can be categorized into C. Difficile, crohn’s disease, inflammatory bowel disease, diabetes, and others. The Clostridium difficile infection (CDI or C. difficile) application segment is expected to register the highest growth during the forecast period. This can be ascribed to the widespread use of FMT in treatment of C.difficile.
Based on region, North America dominated the global microbiome therapeutics market among Europe, Asia Pacific, South America, and Middle East region. The region’s dominance is mostly due to its well-established research capabilities for the creation of innovative treatments. Additionally, several initiatives taken in the region such as the Canadian Microbiome Initiative (CMI) in Canada makes it easier to work with partners and stakeholders. This makes it possible to concentrate research efforts on the creation of microbial medicines.
Major operating companies operating in global microbiome therapeutics market are:
- 4D Pharma plc
- Enterome SA
- Finch Therapeutics Group, Inc.
- Vedanta Bioscience, Inc.
- Seres Therapeutics, Inc.
- Microbiotica Limited
- Destiny Pharma plc
- Taisho Pharmaceutical Holdings Co., Ltd.
- AOBiome Therapeutics, Inc.
- Ferring Pharmaceuticals SA
Customers can also request for 10% free customization on this report.
“The need for precise, reliable, safer, and effective treatment options will drive the growth of global microbiome therapeutics market in the coming years. Similarly, Europe will witness significant growth in the global microbiome market on account of increasing research & development activities, funding, and collaborations in the region. Additionally, emerging startup companies focusing on development of microbiome therapeutic products in the region is expected to further support the market growth. Also, the regulatory scenario in the Europe is not as strict as in North America, thereby supporting the market growth.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“Microbiome Therapeutics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Type (FMT v/s Microbiome Drugs), By Application (C. Difficile, Crohn’s Disease, Inflammatory Bowel Disease, Diabetes, Others) and By Region”, has evaluated the future growth potential of global microbiome therapeutics market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global microbiome therapeutic market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com